Study on prevention of hypercapnia by Nasal High Flow in patients with endoscopic submucosal dissection during intravenous anesthesia

JRCT ID: jRCTs072190022

Registered date:26/08/2019

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Esophagus cancer, Gastric cancer, Colorectal cancer
• Date of first enrollment: 25/12/2019
• Target sample size: 104
• Study type: Interventional
• Intervention(s): NHF intervention

Outcome(s)

Primary Outcome

1) Occurrence of marked hypercarbonemia showing maximum value of percutaneous carbon dioxide concentration over 60 mmHg (equivalent to PaCO2> 55 mmHg) during intravenous anesthesia
2) Area under curve (AUC) of percutaneous carbon dioxide concentration per unit time at intravenous anesthesia
3) Duration of moderate hypercarbonemia showing maximum value of 50mmHg or more (equivalent to PaCO2> 45mmHg) during percutaneous anesthesia with intravenous anesthesia
4) Occurrence of hypoxemia showing 90% or less of the value of percutaneous oxygen saturation during intravenous anesthesia

Secondary Outcome

1) Anesthesia depth assessment (Ramsay scale)
2) Anesthesia dose

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: < 85age old
• Gender: Both

Include criteria

1 Age: Adult patients aged 20 to 85 years of age at the time of consent acquisition
2 Gender: Any question
3 hospitalization / outpatient: hospitalization only
4 Patients who received written consent by their own free will after thorough understanding before participating in this study

Exclude criteria

1 Continuous administration of oxygen by nasal cannula (home oxygen therapy)
2 Patients who cannot breathe in the nose
Patients who need to stop antithrombotic drugs before 3 endoscopes
3 Patients who cannot reduce or stop the antithrombotic drug on the day before the endoscope
4 Patients with a history of pneumothorax
5 Other patients judged by the research director as inappropriate for study
6 Patients who are positive for the new coronavirus (SARS-CoV-2) PCR test

Related Information

• Primary Sponsor: Ayuse Takao
• Source(s) of Monetary Support: Fisher &amp; Paykel Healthcare Limited